Comparison
17 20 Lyase Deficiency Isolated Included CN372394 vs 12q14 Microdeletion Syndrome C4305140
Clinical comparison between 17 20 Lyase Deficiency Isolated Included CN372394 and 12q14 Microdeletion Syndrome for differential diagnosis and treatment planning.
6 comparison axes
Onset
17 20 Lyase Deficiency Isolated Included CN372394
0-16
12q14 Microdeletion Syndrome C4305140
0-2
Onset patterns differ
Severity
17 20 Lyase Deficiency Isolated Included CN372394
severe
12q14 Microdeletion Syndrome C4305140
moderate
Different severity levels
Chronic
17 20 Lyase Deficiency Isolated Included CN372394
Chronic
12q14 Microdeletion Syndrome C4305140
Chronic
Differing course
Communicable
17 20 Lyase Deficiency Isolated Included CN372394
No
12q14 Microdeletion Syndrome C4305140
No
Different transmission
Body System
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
12q14 Microdeletion Syndrome C4305140
congenital
Same/different system
Category
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
12q14 Microdeletion Syndrome C4305140
genetic
Different category
Bottom line
17-20-lyase-deficiency-isolated-included-CN372394 and 12q14-microdeletion-syndrome-C4305140 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 20 Lyase Deficiency Isolated Included CN372394 | 12q14 Microdeletion Syndrome C4305140 | Discriminating power |
|---|---|---|---|
| Pubertal development | Absent or incomplete puberty and sex-steroid deficiency may occur. | Puberty is not the defining feature; developmental delay is more typical. | High |
| Early growth and development | Presentation may emerge from childhood through adolescence rather than at birth. | Concerns often begin in infancy, including growth or developmental delay. | Moderate |
| Congenital anomalies | Genital atypicality may occur in some genetic males; broader malformations are not characteristic. | Variable congenital or dysmorphic features may accompany developmental problems. | Moderate |
When to favor each condition
Choose 17 20 Lyase Deficiency Isolated Included CN372394 when
Disordered puberty or sex-steroid production
The endocrine pattern points toward steroidogenesis rather than a chromosomal syndrome.
High
Suspected CYP17A1-related disorder
Specialist endocrine and genetic assessment can evaluate isolated lyase deficiency.
Moderate
Normal chromosomal microarray but abnormal steroid profile
This combination favors an endocrine diagnosis over 12q14 deletion, pending confirmation.
Moderate
Choose 12q14 Microdeletion Syndrome C4305140 when
Infant with developmental delay and growth concerns
Early multisystem developmental presentation fits the described microdeletion better.
Moderate
Chromosomal testing shows 12q14 deletion
A confirmed deletion establishes the syndrome rather than an enzyme deficiency.
High
Learning difficulties without a steroidogenic pattern
Supportive genetic evaluation is more relevant than endocrine enzyme testing alone.
Moderate
How key tests differ
| Test | 17 20 Lyase Deficiency Isolated Included CN372394 | 12q14 Microdeletion Syndrome C4305140 | Interpretation |
|---|---|---|---|
| Steroid profile | Sex-steroid production may be low, with altered precursors; exact cutoffs are not supplied. | No characteristic steroid abnormality is established. | Abnormal steroids suggest, but do not alone prove, lyase deficiency. |
| Genetic testing | CYP17A1 or related steroidogenic testing may be considered. | Chromosomal microarray or equivalent testing may identify a 12q14 deletion. | The confirmed genetic result distinguishes the conditions. |
| Developmental assessment | Not primarily a developmental-delay diagnosis. | Delay or learning difficulty may be documented and monitored. | Findings guide support but are not diagnostic by themselves. |
Prognosis comparison
17 20 Lyase Deficiency Isolated Included CN372394
- Outcome
- Chronic endocrine condition with outcome depending on timely recognition and individualized care.
- Factors
- Degree of enzyme impairment, puberty and bone-health management, and associated hormonal effects.
12q14 Microdeletion Syndrome C4305140
- Outcome
- Chronic congenital condition; developmental outcome is variable and often moderate in supplied data.
- Factors
- Deletion extent, developmental support, associated anomalies, and access to therapies.
Time frame: Lifelong follow-up may be needed; no reliable mortality estimate is supplied.
Prognosis should be interpreted by clinicians using confirmed genetics and individual assessments.
Complications comparison
| Complication | Presentation |
|---|---|
| Sex-hormone deficiency | May affect puberty, fertility, bone health, or sexual development. Not an established defining complication. Endocrine follow-up is individualized; doses are not specified here. |
| Developmental and learning needs | Not characteristic from the supplied evidence. Delays and learning difficulties may require ongoing support. Needs vary widely among affected people. |
| Associated health issues | Potential adrenal or blood-pressure effects depend on the exact enzymatic pattern. Other congenital or medical issues may occur but are variable. Neither complication profile should be assumed without evaluation. |
Patient education highlights
- HighConfirmation
A single abnormal test is not a diagnosis; specialist confirmation and genetic counseling are important.
- HighDifferent care pathways
One condition centers on endocrine care, while the other centers on developmental and supportive care.
- MediumVariability
Severity and features differ between individuals, so monitoring plans should be personalized.